Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting
Lund, Sweden, 3 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that biomarker data from its OPTIMIZE-1 cli ...
Alligator Bioscience AB carries out directed issues to guarantors in connection with exercise of warrants series TO 12
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator Bioscience announces Henlius receives European orphan drug designation for HLX22 in gastric cancer
Lund, Sweden – 26 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Commission has granted orphan ...
Alligator Bioscience presents OPTIMIZE-1 biomarker data at ASCO 2025 Annual Meeting
Lund, Sweden, 23 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the presentation of biomarker data from its ...
Alligator Bioscience AB announces final outcome of exercise of warrants series TO 12
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Alligator Bioscience announces paediatric study waiver for mitazalimab granted by the European Medicines Agency
Lund, Sweden, 20 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical stage biotechnology company pioneering immuno-o ...
Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 12
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Last day of trading in warrants series TO 12 in Alligator Bioscience is 15 May 2025
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience to attend ASCO 2025 Annual Meeting
Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...